Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer

Patrick C. Ma, Ramasamy Jagadeeswaran, Simha Jagadeesh, Maria S. Tretiakova, Vidya Nallasura, Edward A. Fox, Mark Hansen, Erik Schaefer, Katsuhiko Naoki, Alan Lader, William Richards, David Sugarbaker, Aliya N. Husain, James G. Christensen, Ravi Salgia

Research output: Contribution to journalArticle

396 Citations (Scopus)

Abstract

Non-small cell lung cancer (NSCLC) is a difficult disease to treat. The c-Met receptor is an attractive potential target for novel therapeutic inhibition in human cancers. We provide strong evidence that c-Met is overexpressed, activated, and sometimes mutated in NSCLC cell lines and tumor tissues. Expression of c-Met was found in all (100%) of the NSCLC tumor tissues examined (n = 23) and most (89%) of the cell lines (n = 9). Sixty-one percent of tumor tissues strongly expressed total c-Met, especially adenocarcinoma (67%). Specific expression of phospho-Met (p-Met) [Y1003] and [Y1230/1234/1235] was seen by immunohistochemistry. p-Met expression was preferentially observed at the NSCLC tumor invasive fronts. c-Met alterations were identified within the semaphorin domain (E168D, L299F, S323G, and N375S) and the juxtamembrane domain (R988C, R988C + T1010I, S1058P, and alternative splice product skipping entire juxtamembrane domain) of a NSCLC cell line and adenocarcinoma tissues. We validated c-Met as potential therapeutic target using small interfering RNA down-regulation of the receptor expression by 50% to 60% in NSCLC cells. This led to inhibition of p-Met and phospho-AKT and up to 57.1 ± 7.2% cell viability inhibition at 72 hours. The selective small molecule inhibitor of c-Met SU11274 inhibited cell viability in c-Met-expressing NSCLC cells. SU11274 also abrogated hepatocyte growth factor-induced phosphorylation of c-Met and its downstream signaling. Here, we provide first direct evidence by small interfering RNA targeting and small molecule inhibitor that c-Met is important in NSCLC biology and biochemistry. These results indicate that c-Met inhibition will be an important therapeutic strategy against NSCLC to improve its clinical outcome.

Original languageEnglish
Pages (from-to)1479-1488
Number of pages10
JournalCancer Research
Volume65
Issue number4
DOIs
Publication statusPublished - 2005 Feb 15
Externally publishedYes

Fingerprint

Non-Small Cell Lung Carcinoma
Small Interfering RNA
Mutation
Therapeutics
Neoplasms
Cell Survival
Adenocarcinoma
Semaphorins
((3Z)-N-(3-chlorophenyl)-3-((3,5-dimethyl-4-((4-methylpiperazin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-N-methyl-2-oxo-2,3-dihydro-1H-indole-5-sulfonamide)
Cell Line
Hepatocyte Growth Factor
Tumor Cell Line
Biochemistry
Down-Regulation
Immunohistochemistry
Phosphorylation

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Ma, P. C., Jagadeeswaran, R., Jagadeesh, S., Tretiakova, M. S., Nallasura, V., Fox, E. A., ... Salgia, R. (2005). Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer. Cancer Research, 65(4), 1479-1488. https://doi.org/10.1158/0008-5472.CAN-04-2650

Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer. / Ma, Patrick C.; Jagadeeswaran, Ramasamy; Jagadeesh, Simha; Tretiakova, Maria S.; Nallasura, Vidya; Fox, Edward A.; Hansen, Mark; Schaefer, Erik; Naoki, Katsuhiko; Lader, Alan; Richards, William; Sugarbaker, David; Husain, Aliya N.; Christensen, James G.; Salgia, Ravi.

In: Cancer Research, Vol. 65, No. 4, 15.02.2005, p. 1479-1488.

Research output: Contribution to journalArticle

Ma, PC, Jagadeeswaran, R, Jagadeesh, S, Tretiakova, MS, Nallasura, V, Fox, EA, Hansen, M, Schaefer, E, Naoki, K, Lader, A, Richards, W, Sugarbaker, D, Husain, AN, Christensen, JG & Salgia, R 2005, 'Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer', Cancer Research, vol. 65, no. 4, pp. 1479-1488. https://doi.org/10.1158/0008-5472.CAN-04-2650
Ma, Patrick C. ; Jagadeeswaran, Ramasamy ; Jagadeesh, Simha ; Tretiakova, Maria S. ; Nallasura, Vidya ; Fox, Edward A. ; Hansen, Mark ; Schaefer, Erik ; Naoki, Katsuhiko ; Lader, Alan ; Richards, William ; Sugarbaker, David ; Husain, Aliya N. ; Christensen, James G. ; Salgia, Ravi. / Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer. In: Cancer Research. 2005 ; Vol. 65, No. 4. pp. 1479-1488.
@article{bfcc1f82a5e14c748aa951cc07772e2a,
title = "Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer",
abstract = "Non-small cell lung cancer (NSCLC) is a difficult disease to treat. The c-Met receptor is an attractive potential target for novel therapeutic inhibition in human cancers. We provide strong evidence that c-Met is overexpressed, activated, and sometimes mutated in NSCLC cell lines and tumor tissues. Expression of c-Met was found in all (100{\%}) of the NSCLC tumor tissues examined (n = 23) and most (89{\%}) of the cell lines (n = 9). Sixty-one percent of tumor tissues strongly expressed total c-Met, especially adenocarcinoma (67{\%}). Specific expression of phospho-Met (p-Met) [Y1003] and [Y1230/1234/1235] was seen by immunohistochemistry. p-Met expression was preferentially observed at the NSCLC tumor invasive fronts. c-Met alterations were identified within the semaphorin domain (E168D, L299F, S323G, and N375S) and the juxtamembrane domain (R988C, R988C + T1010I, S1058P, and alternative splice product skipping entire juxtamembrane domain) of a NSCLC cell line and adenocarcinoma tissues. We validated c-Met as potential therapeutic target using small interfering RNA down-regulation of the receptor expression by 50{\%} to 60{\%} in NSCLC cells. This led to inhibition of p-Met and phospho-AKT and up to 57.1 ± 7.2{\%} cell viability inhibition at 72 hours. The selective small molecule inhibitor of c-Met SU11274 inhibited cell viability in c-Met-expressing NSCLC cells. SU11274 also abrogated hepatocyte growth factor-induced phosphorylation of c-Met and its downstream signaling. Here, we provide first direct evidence by small interfering RNA targeting and small molecule inhibitor that c-Met is important in NSCLC biology and biochemistry. These results indicate that c-Met inhibition will be an important therapeutic strategy against NSCLC to improve its clinical outcome.",
author = "Ma, {Patrick C.} and Ramasamy Jagadeeswaran and Simha Jagadeesh and Tretiakova, {Maria S.} and Vidya Nallasura and Fox, {Edward A.} and Mark Hansen and Erik Schaefer and Katsuhiko Naoki and Alan Lader and William Richards and David Sugarbaker and Husain, {Aliya N.} and Christensen, {James G.} and Ravi Salgia",
year = "2005",
month = "2",
day = "15",
doi = "10.1158/0008-5472.CAN-04-2650",
language = "English",
volume = "65",
pages = "1479--1488",
journal = "Journal of Cancer Research",
issn = "0008-5472",
publisher = "American Association for Cancer Research Inc.",
number = "4",

}

TY - JOUR

T1 - Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer

AU - Ma, Patrick C.

AU - Jagadeeswaran, Ramasamy

AU - Jagadeesh, Simha

AU - Tretiakova, Maria S.

AU - Nallasura, Vidya

AU - Fox, Edward A.

AU - Hansen, Mark

AU - Schaefer, Erik

AU - Naoki, Katsuhiko

AU - Lader, Alan

AU - Richards, William

AU - Sugarbaker, David

AU - Husain, Aliya N.

AU - Christensen, James G.

AU - Salgia, Ravi

PY - 2005/2/15

Y1 - 2005/2/15

N2 - Non-small cell lung cancer (NSCLC) is a difficult disease to treat. The c-Met receptor is an attractive potential target for novel therapeutic inhibition in human cancers. We provide strong evidence that c-Met is overexpressed, activated, and sometimes mutated in NSCLC cell lines and tumor tissues. Expression of c-Met was found in all (100%) of the NSCLC tumor tissues examined (n = 23) and most (89%) of the cell lines (n = 9). Sixty-one percent of tumor tissues strongly expressed total c-Met, especially adenocarcinoma (67%). Specific expression of phospho-Met (p-Met) [Y1003] and [Y1230/1234/1235] was seen by immunohistochemistry. p-Met expression was preferentially observed at the NSCLC tumor invasive fronts. c-Met alterations were identified within the semaphorin domain (E168D, L299F, S323G, and N375S) and the juxtamembrane domain (R988C, R988C + T1010I, S1058P, and alternative splice product skipping entire juxtamembrane domain) of a NSCLC cell line and adenocarcinoma tissues. We validated c-Met as potential therapeutic target using small interfering RNA down-regulation of the receptor expression by 50% to 60% in NSCLC cells. This led to inhibition of p-Met and phospho-AKT and up to 57.1 ± 7.2% cell viability inhibition at 72 hours. The selective small molecule inhibitor of c-Met SU11274 inhibited cell viability in c-Met-expressing NSCLC cells. SU11274 also abrogated hepatocyte growth factor-induced phosphorylation of c-Met and its downstream signaling. Here, we provide first direct evidence by small interfering RNA targeting and small molecule inhibitor that c-Met is important in NSCLC biology and biochemistry. These results indicate that c-Met inhibition will be an important therapeutic strategy against NSCLC to improve its clinical outcome.

AB - Non-small cell lung cancer (NSCLC) is a difficult disease to treat. The c-Met receptor is an attractive potential target for novel therapeutic inhibition in human cancers. We provide strong evidence that c-Met is overexpressed, activated, and sometimes mutated in NSCLC cell lines and tumor tissues. Expression of c-Met was found in all (100%) of the NSCLC tumor tissues examined (n = 23) and most (89%) of the cell lines (n = 9). Sixty-one percent of tumor tissues strongly expressed total c-Met, especially adenocarcinoma (67%). Specific expression of phospho-Met (p-Met) [Y1003] and [Y1230/1234/1235] was seen by immunohistochemistry. p-Met expression was preferentially observed at the NSCLC tumor invasive fronts. c-Met alterations were identified within the semaphorin domain (E168D, L299F, S323G, and N375S) and the juxtamembrane domain (R988C, R988C + T1010I, S1058P, and alternative splice product skipping entire juxtamembrane domain) of a NSCLC cell line and adenocarcinoma tissues. We validated c-Met as potential therapeutic target using small interfering RNA down-regulation of the receptor expression by 50% to 60% in NSCLC cells. This led to inhibition of p-Met and phospho-AKT and up to 57.1 ± 7.2% cell viability inhibition at 72 hours. The selective small molecule inhibitor of c-Met SU11274 inhibited cell viability in c-Met-expressing NSCLC cells. SU11274 also abrogated hepatocyte growth factor-induced phosphorylation of c-Met and its downstream signaling. Here, we provide first direct evidence by small interfering RNA targeting and small molecule inhibitor that c-Met is important in NSCLC biology and biochemistry. These results indicate that c-Met inhibition will be an important therapeutic strategy against NSCLC to improve its clinical outcome.

UR - http://www.scopus.com/inward/record.url?scp=13944276728&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=13944276728&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-04-2650

DO - 10.1158/0008-5472.CAN-04-2650

M3 - Article

VL - 65

SP - 1479

EP - 1488

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0008-5472

IS - 4

ER -